-
1 week ago | 
insideprecisionmedicine.com | Sophia Ktori |Kathy Vuksanaj
A study led by NYU Langone Health and its Perlmutter Cancer Center scientists found that monitoring DNA fragments shed by dying tumor cells in the blood may accurately predict skin cancer recurrence. In the Phase III COMBI-AD clinical trial, researchers observed that about 80% of stage III melanoma patients with detectable circulating tumor DNA (ctDNA) prior to treatment eventually experienced a recurrence.
-
3 weeks ago | 
insideprecisionmedicine.com | Larissa Warneck-Silvestrin |Kathy Vuksanaj
With the advent of next-generation sequencing (NGS) technologies just over a decade ago, genomic information became available not only in labs, but also in clinical practice. Today, genomic testing is starting to play an important role in cancer patient care. Knowing the genetic makeup of a tumor can help oncologists determine the best therapeutic options for a patient, making genomic testing a growing part of precision medicine.
-
3 weeks ago | 
insideprecisionmedicine.com | Helen Albert |Kathy Vuksanaj
Over the last decade, the cell and gene therapy space has changed beyond recognition. The field has experienced ups and downs, but such advanced therapeutics are becoming more mainstream and moving into spaces outside cancer and rare diseases. At the end of 2015, only three cell and gene therapy products had been approved by the FDA. By the end of 2024, this figure had increased to 43 products, with more therapies approved every year.
-
3 weeks ago | 
insideprecisionmedicine.com | Jonathan Grinstein |Kathy Vuksanaj
In the fast-evolving world of genetic innovation, few leaders embody the spirit of discovery and application like Brad Ringeisen, PhD, executive director of the Innovative Genomics Institute (IGI), does.
-
3 weeks ago | 
insideprecisionmedicine.com | Helen Albert |Kathy Vuksanaj
Cancer therapeutics has advanced enormously over the last 20 years, with many products developed to harness or target the immune system to better treat a range of tumors. One such approach combines antibodies with tumor targeting drugs to form antibody-drug conjugates or ADCs.These cancer targeting agents have several advantages such as precise targeting of cancer cells, less toxicity than traditional chemotherapy, and enhanced efficacy in difficult-to-treat cancers.
-
1 month ago | 
insideprecisionmedicine.com | Sophia Ktori |Kathy Vuksanaj
University of Pittsburgh researchers have uncovered a novel trigger for a lethal form of ovarian cancer.
-
2 months ago | 
insideprecisionmedicine.com | Helen Albert |Kathy Vuksanaj
Antimicrobial drugs have saved billions of lives over the last century, but during the last 30 years, deaths due to antimicrobial resistance (AMR) have increased exponentially. While there are many early-stage companies and researchers working to bring new treatments and diagnostics to market, success seems difficult due to reimbursement issues.
-
2 months ago | 
insideprecisionmedicine.com | Malorye Allison Branca |Kathy Vuksanaj
In an interesting study published in 2022, a dozen physicians from multiple clinics gathered comprehensive genomic profiling (CGP) results for 297 patients. Of these, 221 patients met inclusion criteria for the study, which was looking at the effect of using CGP to prescribe targeted therapies. Twenty-one of these patients received targeted therapy and clinical benefit was seen in nine patients (4%), two of whom were exceptional responders (1%). This study took place in India.
-
2 months ago | 
insideprecisionmedicine.com | Jonathan Grinstein |Kathy Vuksanaj
Before dosing the first autoimmune disease patient with chimeric antigen receptor T cell (CAR T) therapy, Georg Schett, MD, asked his team at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), “Why don’t we use CAR T cells to deeply deplete the B-cells?” Schett believed that CAR T cells—living medicines that can proliferate and kill cells anywhere in the body—could cure autoimmune diseases. But the “right” patient was missing.
-
2 months ago | 
insideprecisionmedicine.com | Clara Fernandez |Clara Fernández |Kathy Vuksanaj
Precision medicine has largely been driven by rapid progress in genomics over the past two decades, with advances in next-generation sequencing enabling massive parallelization with unprecedented speed. However, interest is now increasingly shifting toward proteomics to gather insights into the underlying mechanisms of disease. After all, it is proteins that execute the instructions encoded in our genes and are largely responsible for the myriad of cellular processes that keep us alive.
